![]() |
|
|
Vol. 293, Issue 2, 494-500, May 2000
The Rockefeller University, New York, New York (N.G.A., S.J., G.S.D., A.K.); and Department of Pharmacology, New York Medical College, Valhalla, New York (L.Y., B.A.Z., M.L.-S., J.M.)
| |
Abstract |
|---|
|
|
|---|
Intravenous administration of an adenovirus human heme oxygenase (HO)-1 gene construct to rats resulted in functional expression of human HO-1 in brain, heart, lung, liver, and kidney. Because accurate assessment of human HO-1 mRNA in various tissues by Northern analysis is not sufficiently sensitive, we developed a method for quantifying human HO-1 mRNA copies with quantitative reverse transcription- polymerase chain reaction techniques; this allowed us to use the same primers for both the sample and internal standard. Administration of the adenovirus human HO-1 gene resulted in the detection of human HO-1 mRNA in various tissues with the highest levels seen in the kidney followed, in order, by lung > liver > brain > heart. Human HO-1 was detectable for up to 4 weeks in all tissues studied. Administration of adenovirus human HO-1 resulted in maximal increase of HO activity after 1 to 2 weeks in rats. The increase in HO activity due to gene transfer also was associated with a parallel decrease (~25%) in cytochrome P-450 (CYP) content and in CYP-dependant arachidonic acid metabolism. In addition, we investigated the possibility that the human HO-1 gene altered the expression of the endogenous rat enzyme after administration of cobalt chloride s.c.. Cobalt chloride administration resulted in increased HO activity in all tissues examined in rats transduced with the human HO-1 gene to the same degree as in nontransduced rats. The metal was a more potent inducer of renal HO activity than was the adenoviral-mediated human HO-1 vector. The increase in HO activity after adenoviral-mediated human HO-1 transfer was associated with a decrease in microsomal heme-CYP and CYP activity. The increase in HO-1 activity after adenovirus-mediated human HO-1 gene transfer may prove useful as a means of selectively increasing enzyme activity in a specific organ and regulating homeostasis by modulation of vasoactive molecules such as carbon monoxide and bilirubin and, in addition, providing a means of delivering the human HO-1 gene for experimental purposes.
| |
Introduction |
|---|
|
|
|---|
The
vital role of heme in mammalian physiology is attested to by its
function as the prosthetic group of a variety of important hemeproteins
that are essential for various cellular processes. Heme is involved in
electron transfer as the prosthetic group of cytochromes, in the
enzymatic decomposition of
H2O2 as the prosthetic
group of catalase and peroxidase, in the generation of nitric oxide as
the prosthetic group of nitric oxide synthase, and in the manufacture
of vasoactive eicosanoids as the prosthetic group of cytochrome P-450
(CYP) and cyclooxygenase (Kappas and Drummond, 1986
; Abraham et al.,
1996
). Cellular levels of heme are regulated by its rate of synthesis
and degradation. Heme catabolism occurs by oxidative cleavage of the
-methene bridge of the molecule, eventually leading to the formation
of equimolar amounts of bilirubin and carbon monoxide. The heme
oxygenase (HO) system is the rate-limiting step in heme degradation. To
date, three HO isoforms (HO-1, HO-2, and HO-3) have been identified
that catalyze this reaction (Abraham et al., 1987
; Maines, 1988
;
McCoubrey et al., 1992
; Shibahara et al., 1993
). HO-1 is a
32-kDa heat shock protein (Mitani et al., 1989
; Dwyer et al.,
1992
) that is inducible by numerous noxious stimuli (Maines and Kappas,
1974
; Lutton et al., 1992
; Lu et al., 1998
). HO-2 is a constitutively
synthesized 36-kDa protein that is abundant in brain and testis
(Maines, 1988
). HO-3 is related to HO-2 but is the product of a
different gene, and its ability to catalyze heme degradation is much
less than that of HO-2 (McCoubrey et al., 1997
). Increasing data reveal
that HO and its metabolic products carbon monoxide and bilirubin play
important roles in numerous biological processes, especially in
endothelial cell vasodilating responses and in cellular antioxidative
reactions (Stocker et al., 1987
; Ingi and Ronnett, 1995
; Suttner et
al., 1999
), and evidence that the suppression of HO-1 may not lead to
cell protection also is accumulating (da Silva et al., 1996
; Suttner et
al., 1999
). The reasons for this paradox are not clear but the evidence
shows that HO can mediate both cell protection and cell injury,
depending on experimental conditions (Nutter et al., 1994
; Kadoya et
al., 1995
; da Silva et al., 1996
). Carbon monoxide produced by HO-1 and
HO-2 has been implicated as a physiological regulator of cGMP and
vascular tone (Ishizaka et al., 1994
; Morita et al., 1995
; Durante et
al., 1997
; Sammut et al., 1998
; Yang et al., 1999
). We and others have
demonstrated that induction of epithelial HO-1 in an animal model of
contact lens-induced hypoxic injury greatly attenuates corneal surface
inflammatory responses, and a similar effect is observed in an
experimental model of inflammation in rats (Willis et al., 1996
;
Laniado-Schwartzman et al., 1997
).
We have previously shown that overexpression of HO-1 in coronary
endothelial cells results in resistance to hemoglobin-induced injury
(Abraham et al., 1995b
). Recent studies also have shown that
transfection of rat HO-1 cDNA to human pulmonary epithelial cells can
increase cell viability in hyperoxia (Choi et al., 1995
; Suttner et
al., 1999
). Moderate overexpression of HO-1 provides protection against
oxidative injury (Suttner et al., 1999
). Conversely, deficient HO
expression in mammalian cells contributes to reduced stress defense
(Poss and Tonegawa, 1997b
; Yachie et al., 1999
). More recently, Hancock
et al. (1998)
have shown that HO-1 induction prevents oxidant-stressed
endothelial up-regulation of adhesion molecules and development of
transplant arteriosclerosis in normal mice, suggesting that a moderate
increase in HO activity may be beneficial in resistance to oxidants. In
contrast, selective inhibition of HO-1 gene expression with antisense
oligonucleotides is associated with enhancement of adhesion molecule
expression in endothelial cells and with inflammation (Wagener et al.,
1999
).
The present study was designed to determine whether the human HO-1 gene could be introduced into various rat tissues by i.v. administration of a recombinant replication-deficient adenoviral human HO-1 cDNA construct. Furthermore, we assessed the functional expression of the human HO-1 gene on HO-1 mRNA, and protein and cellular heme content and CYP-dependent arachidonic acid metabolism. The results reported herein demonstrate that administration of an adenoviral-mediated human HO-1 gene vector in adult rats results in a transient increase in human HO-1 mRNA production and HO-1 protein and an increase in total HO enzyme activity. Transduction of the HO-1 gene in vivo was associated with a decrease in the activity of one of the heme-dependent CYP epoxygenases. These data thus directly demonstrate that an in vivo increase in human HO-1 gene expression would be expected to decrease cellular free heme concentration, with a consequent decrease in CYP activities that are known to participate in generation of inflammatory mediators.
| |
Materials and Methods |
|---|
|
|
|---|
Construction of Adenoviral Vector Containing Human HO-1
cDNA.
We constructed the human HO-1 cDNA with adenovirus vector
with a mammalian transfection kit from Stratagene (La Jolla, CA) as
previously described (Abraham et al., 1995a
). Briefly, the human cDNA
plasmid was constructed as follows: an Xhol-Xbal
fragment of a human HO-1 expression vector pRc/CMVHO-1 was cloned
between Xhol and Xbal of the pBacPAC8 to generate
pBacPAC8human HO-1. The Bg1II-BamHI fragment of
the pBacPAC8HHO was then introduced into the Bg1II site of
pAdBg1II. A human embryonic cell line, 293 cells (no.
1573-CRL; American Type Culture Collection, Manassas, VA), was
cotransfected with 10 µg of EcoRI-digested adenoviral human HO-1 and 1 µg of ClaI-digested dL7001DNA by
calcium-phosphate coprecipitation with a mammalian transfection kit.
Human HO-1 adenovirus construct was replicated and encapsulated into an
infectious virus. After a 5-day incubation period, the virus plaque
locations were marked on the flasks, and the resultant cytopathic
effect on the monolayers was observed microscopically until the plaque reached an adequate size. The plaques were purified and checked for the
presence of human HO-1 by polymerase chain reaction (PCR) with HO-1
specific primer, and amplified by propagation in the 293 cell line.
HO-1 adenovirus was released and collected from infected cells 2 days
after infection with rupture of the cells by freezing and thawing
several times (usually three times) and concentrated by centrifugation
with Ultrafree-MC filters (Millipore, Bedford, MA). The virus titers
were determined by plaque assay with 293 cells. The virus was stored at
80°C until use.
In Vivo Gene Transfer. Sprague-Dawley male rats (150-180 g) purchased from Taconic Farms (Germantown, NY) were injected i.v. with human HO-1-adenovirus suspension (1012 pfu/ml/animal) in the tail vein. The control group was injected with an equal volume of saline. The animals were housed in The Rockefeller University Laboratory Animal Research Center in a controlled environment with a 12-h light/dark cycle. The animals were acclimatized for 1 week before the start of the experiment. A minimum of three animals was used for each data point and animals were sacrificed at the times indicated on the legends to the figures and tables. CoCl2 (Mallinckrodt, St. Louis, MO) was dissolved in saline and administered subcutaneously in the nuchal region at a dose of 250 µmol/kg b.wt. 16 h before sacrifice. Control animals were administered an equivalent volume of saline.
RNA Extraction and Reverse Transcription (RT)-PCR. The rat tissues were ground in liquid nitrogen and total RNA was extracted with guanidine thiocyanate, first purified with phenol-chloroform, followed by an additional purification with chloroform, and then precipitated with isopropanol. Total RNA was resuspended in autoclaved diethyl pyrocarbonate-water, and quantitated by absorbency measurement with a Beckman DU7400 spectrophotometer. To verify the quality of RNA and analyze the RNA, 10 µg of total RNA was denatured and size-separated by electrophoresis on a 1% agarose gel containing 2.2 M formaldehyde. The integrity of the samples was checked with ethidium bromide staining solution under UV light.
Primers were designed to amplify specific fragments of human HO-1 and/or rat HO-1. The primers used do not recognize HO-2 sequences. The RT-PCR for human HO-1 was performed by using the Advantage RT-for-PCR kit (Clontech Laboratories, Palo Alto, CA), and the primers described to amplify an RT-PCR product with a predicted size of 555 base pairs (bp). Briefly, 1 µg of total RNA was reverse transcribed with the oligo (dT18) primer to synthesize the second strand and to obtain the cDNA. The reverse transcription was performed at 42°C for 1 h, the reaction was stopped by heating at 95°C for 5 min and the reaction mixture was then placed on ice. The PCR was performed by adding the PCR mix prepared with sense primer (5'-CAGGCAGAGAATGCTGAGTTC-3'), antisense primer (5'-GATGTTGAGCAGGAACGCAGT-3'), dNTP, Taq polymerase, [32P]dCTP, and reaction buffer. We performed 40 cycles with the following profile: denaturation at 95°C for 1 min, annealing at 55°C for 1 min, and elongation-extension at 72°C for 2 min. The last cycle was followed by a final extension at 72°C for 10 min. The PCR products were electrophoresed on a 4% acrylamide gel. The gel was then dried and exposed to X-ray film. To amplify the endogenous rat HO-1, we used primers designed from the rat cDNA sequence (sense primer: 5'-TGAAGGAGGCCACCAAGGAG-3'; antisense primer: 5-CCCCTGAGAGGTCACCCAGG-3'), which amplify a 356-bp fragment. RT-PCR was performed as described above.Quantitation of Human HO-1 mRNA Copies.
The number of human
HO-1 mRNA copies was measured in rat tissues after adenoviral-mediated
gene transfer according to published methods (Goodman et al., 1996
;
Abraham, 1998
). Briefly, the plasmid pCMV-human HO-1 was linearized
with Eco47III (a single restriction site in human HO-1 cDNA
at position 420 bp). The linearized plasmid was digested with Bal 31 nuclease for 5 min to digest nucleotides and create a mutation. After
this digestion, the construct was ligated with T4 DNA ligase. After
transformation into JM109 Escherichia coli competent
bacteria, several clones were analyzed for the size of the mutated
human HO-1 cDNA that resulted from the digestion by Bal 31 and for the
presence of the Eco47 III restriction site. One clone was selected with
~50 bp truncated from the original cDNA of human HO-1. This clone was
amplified and the insert, excised from the vector with
HindIII, was purified. The amplified products were used as
an internal standard in the competitive versus noncompetitive amplification of the human HO-1 mRNA. Various amounts of total RNA from
human kidney were subjected to RT-PCR alone or as a mixture with a
fixed amount of the mutated insert, which is 50 bp shorter than the
amplified human HO-1 mRNA PCR products. As the amount of one template
increased, the chance of the other template being amplified declined
(eventually, the portion of the other template became too small to be
significant). We have previously shown that when the amount of internal
standard was included in the RT-PCR, the amount of amplified human
template decreased (Abraham, 1998
). Because the internal standard is
generated from the human HO-1 gene and exhibits 100% homology to human
HO-1 mRNA, both targets, human HO-1 mRNA and the internal standard,
could be amplified with an equivalent efficiency. Respective templates
are identified by their differences in size after electrophoresis on
acrylamide gel and are quantitified by densitometry or the
radioactivity count after the bands were excised from the gel (Abraham,
1998
).
HO Activity Measurement.
Enzyme activity was measured with
microsomes from nontransfected and transfected rat tissues. Microsomes
were prepared as previously described. Microsomes were incubated with
hemin, rat liver cytosol, MgCl2,
glucose-6-phosphate dehydrogenase, glucose 6-phosphate, and
NADP+ in potassium phosphate buffer (0.1 M, pH
7.4) for 10 min at 37°C. Placing the tubes on ice stopped the
reaction. The amount of bilirubin generated was estimated with an
extinction coefficient of 40 mM/cm as previously described (Abraham et
al., 1987
).
CYP-Arachidonic Acid Metabolism Assay.
CYP, arachidonic acid
metabolism, and heme were measured as previously described (Fuhrop and
Smith, 1975
; Schwartzman et al., 1990
; da Silva et al., 1994
). Briefly,
microsomes prepared from renal tissues (150 µg) were preincubated
with [1-14C]arachidonic acid (0.4 µCi; 7 nmol) in 100 mM potassium phosphate buffer, pH 7.4, containing 10 mM
MgCl2 for 3 min at 37°C. NADPH (1 mM) was added
and the reaction mixture, with a final volume of 0.3 ml, was incubated
for 30 min at 37°C. The reaction was terminated by acidification to
pH 3.5 to 4.0 with 2 M formic acid, and metabolites were extracted with
ethyl acetate. The final extract was evaporated under nitrogen,
resuspended in 50 µl of methanol, and injected into the HPLC column.
Reversed-phase HPLC was performed on a 5-µm ODS-Hypersil column,
4.6 × 200 mm (Hewlett Packard, Palo Alto, CA) with a linear
gradient ranging from acetonitrile/water/acetic acid (50:50:0.1) to
acetonitrile/acetic acid (100:0.1) at a flow rate of 1 ml/min for 30 min. The elution profile of the radioactive products was monitored by a
flow detector (In/us System Inc., Tampa, FL). The identity of
epoxide and hydroxy-6,8,11,14-eicosatetraenoic acid was confirmed by
its comigration with an authentic standard (Schwartzman and Abraham,
1990
; Schwartzman et al., 1990
).
| |
Results |
|---|
|
|
|---|
Adenovirus-Mediated Expression of Human HO-1 mRNA in 293 Cells and
in Rat Tissues.
Figure 1 represents
the PCR products of the adenoviral human HO-1 construct in culture
media of 293 cells transfected with the adenoviral human HO-1
construct. Lane 1 indicates the absence of a hybridizable band in
nontransduced 293 cells. The culture media of the 293 cell line
transfected with adenoviral human HO-1 (lane 2) gave a positive signal
when amplified with human HO-1 primer, with a predicted size of 555 bp.
The adenovirus without the human HO-1 gene (lane 3) gave no signal. The
human HO plasmid is shown in lane 4 as a positive control.
|
Quantitation of Human HO-1 mRNA after Adenovirus Gene
Transfer.
To quantitate the total amount of human HO-1 mRNA
generated in rat tissues after adenoviral vector human HO-1 gene
transfer, various amounts of total RNA from rat kidney (containing
human HO-1 mRNA) were subjected to RT-PCR alone or as a mixture with a
fixed amount of the internal standard. In the combined PCR, internal
standard is added at the PCR step, and the RT is performed with oligo
(dT) 18 primers as described in Materials and Methods. Respective templates are identified by their differences in size (Fig.
2). As seen in Fig. 2, an internal
standard of human HO-1 cDNA at a concentration of 20 fg was amplified
to maximum levels when rat RNA, which contains human RNA, was at 10 ng
(lane 1). As rat RNA was increased, the amount of the competitive
internal standard amplified decreased (Fig. 2, lanes 2 and 3, respectively). When rat renal RNA level was 150 ng (lane 4) the amount
of the internal standard and human HO-1 RNA within rat RNA was
amplified equally. Because the internal standard, 20 fg of HO-1 RNA,
contains 500 bp consisting of 3.64 × 104
molecules, the amount of human HO-1 mRNA present in 150 ng total rat
RNA was equivalent to 242 mRNA copies. The average amount of human HO-1
mRNA present in 150 ng of RNA was 320 ± 125 mRNA copies
(n = 3). It has been previously shown that the number
of normal human liver and kidney HO-1 molecules is 750 ± 980 and 1100 ± 1300 molecules/µg RNA, respectively. Therefore,
adenoviral-mediated HO-1 gene transfer into the rat resulted in a
generation of ~50% of the basal levels of human HO-1 mRNA in rat
tissues with a significant increase in the basal activity of endogenous
HO activity. Analogously, it has been shown that administration of
CoCl2 at a dose of 250 µmol/kg into rat kidney
resulted in elevation of endogenous rat renal HO-1 ~20-fold, with a
reciprocal decrease in heme-protein content (Sacerdoti et al., 1989
).
|
Evaluation of Human HO-1 Gene in Rat Tissue. Once the method was established, we examined the expression of endogenous HO-1 in rat tissues from animals administered adenoviral human HO-1. Rats were injected with adenoviral human HO-1 vector, and the presence of the human HO-1 gene was examined with respect to time in the brain, heart, lung, liver, and kidney of the animals. The ability of adenovirus to enter rat brain tissue led us to evaluate the possibility that expression of human HO-1 mRNA in this tissue was due to contamination from blood. We examined both blood cells and plasma over the course of the experiment for the presence of human HO-1 mRNA. No human HO-1 mRNA was detectable (data not shown). Positive signals were obtained for the human HO-1 gene when amplified with human HO-1 primers at 1 day, and 1, 2, and 4 weeks, in all tissues examined after injection of adenoviral-human HO construct (Table 1). There was no evidence of human HO-1 in rat tissues 8 weeks after human HO-1 gene transfer (data not shown). The highest tissue levels of human HO-1, in lung and liver, were obtained 2 weeks after human HO-1 gene transfer and declined with time (Table 1). The levels of human HO-1 mRNA were increased after 1 day (Fig. 3, lane 2). The strongest human HO-1 signal was obtained in the kidney 1 to 2 weeks after gene transfer (Fig. 3, lanes 4 and 5, respectively). Administration of adenovirus did not result in up-regulation of endogenous rat HO-1 or GAPDH mRNA (Fig. 3, middle and bottom, respectively).
|
|
Enhancement of HO Activity in Rat Liver and Kidney Injected with Adenoviral Human HO-1 Gene Construct. We examined HO enzymatic activity in transfected kidney and liver tissues obtained from rats pretreated with adenoviral human HO-1. Rats administered empty virus served as controls; the results are depicted in Table 2. The basal levels of HO activity in rat liver and kidney were 0.93 ± 0.2 and 0.79 ± .08 nmol bilirubin/mg/h, respectively. Interestingly, HO activity in the kidney was significantly up-regulated 1 day after adenoviral administration (P < .05). HO activity had returned to the basal levels 4 weeks after Adv-HO-1 gene administration. HO activity was significantly increased after 1 day of adenoviral human HO-1 vector administration and was increased by 1.5- and 2.5-fold in liver and kidney, respectively, after 1 and 2 weeks of adenoviral human HO-1 administration.
|
Effect of Adenoviral Human HO-1 Gene Construct on Induction of Rat Endogenous HO Activity and mRNA. To further ascertain the effect of administration of the adenovirus-mediated human HO-1 gene on the endogenous rat HO-1 gene, we examined the effect of CoCl2 on rat HO activity, and on microsomal protein and rat HO-1 mRNA in total RNA. Rats were administered adenoviral human HO-1 gene at a concentration of 1012 plaque-forming units (pfu)/ml/animal, and 7 and 14 days later CoCl2 was administered at a dose of 250 µmol/kg. The animals were sacrificed 16 h after CoCl2 administration and HO activity was measured in the rat kidney; the results are described in Table 3. There was an increase in human HO-1 mRNA in rat kidney and other tissues examined similar to that seen in Table 1 (data not shown). Administration of CoCl2 to rats receiving empty virus or rats receiving the human HO-1 gene responded in a similar manner. CoCl2 administration increased HO activity from 0.79 ± 0.07 to 2.71 ± 0.50 nmol bilirubin/ng/h. There was an additive increase in HO activity in rats receiving CoCl2 and adenoviral human HO-1 gene compared with rats receiving human HO-1 gene or rats receiving CoCl2. This is due to CoCl2 activation of rat HO-1 promoter and enhancement of rat HO-1 mRNA. Because the adenoviral human HO-1 gene construct lacks the human HO-1 promoter, CoCl2 was unable to activate the human HO-1 gene; therefore, administration of CoCl2 did not increase HO activity more than an additive degree. Similarly, in the 2-week experiments, CoCl2 and the adenoviral human HO-1 construct increased HO activity to 2.71 ± 0.5 and 1.57 ± 0.09 nmol bilirubin/ng/h, respectively. The increase in expression of rat HO activity was associated with an ~20-fold increase in rat HO-1 mRNA (Fig. 4, lane 4). Administration of CoCl2 to transgenic rats with human HO-1 produced a response to a similar degree as in rats that receiving control vector (lanes 5 and 6). These results show that administration of adenovirus-mediated human HO-1 gene to rat tissues such as kidney and brain did not suppress the expression of endogenous HO, and that CoCl2, enhanced endogenous rat HO-1 without activation of the promoterless human HO-1 gene in the adenoviral construct.
|
|
Effect of Adenoviral Human HO-1 Administration on CYP-Arachidonic
Acid Metabolism in Rats.
One of the means by which the activity
and levels of CYP enzymes can be manipulated is by decreasing heme
availability (Levere et al., 1990
). We therefore studied the effect of
adenoviral human HO-1 vectors on CYP content and activity. We examined
whether elevation of HO activity after adenoviral gene transfer
modulated heme-dependent enzyme proteins such as CYP content and
activity. Two weeks after adenovirus-mediated HO-1 gene transfer, we
measured CYP content and CYP activity as determined by arachidonic acid metabolites. The basal level of CYP content in the kidney was 652 ± 174 pmol/mg protein (mean ± S.D; n = 3); 14 days after adenoviral human HO-1 administration, the level of CYP had
decreased to 510 ± 129 pmol/mg protein (mean ± S.D;
n = 3; P < .05). Because CYP isozymes
are involved in the metabolism of many drugs and chemicals, including
arachidonic acid, we further investigated the question of whether a
correlation could be made between adenoviral-mediated HO-1 gene
expression and one of the CYP-dependent arachidonic acid metabolic
enzymes, namely, the CYP enzyme epoxygenases. Arachidonic acid is
oxygenated by renal cortical CYP to the epoxygenase product 11,12-epoxyeicosatrienoic acid and its hydrolytic metabolite
11,12-dihydroxyeicosatrienoic acid. The levels of CYP epoxygenase as
measured by the production of 11,12-epoxyeicosatrienoic acid were
decreased by 35% in rats transduced with human HO-1 gene (Fig.
5). It is clear that the adenoviral-mediated human HO-1 gene transfer resulted in a significant decrease in a heme-CYP activity in renal tissues.
|
| |
Discussion |
|---|
|
|
|---|
We describe in this report that overexpression of human HO-1 by
gene transfer can modulate renal cortical heme content and CYP
epoxygenase activity. These data establish that i.v. delivery of an
adenovirus-mediated human HO-1 gene construct in rats resulted in
expression of human HO-1 mRNA in several tissues (liver, kidney, heart,
lung, and brain). By use of specific primers for human and rat HO-1, it
was shown that 1) the transduced gene could be detected for up to 4 weeks; 2) transduction of human HO-1 to renal cortical tissues resulted
in a decrease of heme-dependent CYP epoxygenase activity; and 3) the
transduced human HO-1 gene increased HO activity without altering
expression of the endogenous HO-1 gene or the inductive response of the
endogenous rat HO-1 gene to CoCl2, a known potent
inducer of HO-1 (Maines and Kappas, 1975
). Overexpression of HO-1 by
inducers such as CoCl2,
SnCl2, and heme has been associated with an
increase in carbon monoxide production and a decrease in renal activity
of CYP epoxygenases that synthesize vasoactive eicosanoids and has
decreased blood pressure in spontaneous hypertensive rats (Schwartzman
et al., 1991
; Imig et al., 1994
). Furthermore, Panahian et al. (1999)
have reported that overexpression of HO-1 may offer protection against
cerebral artery occlusion in the rat brain. In the present study, the
adenoviral human HO-1 gene construct was shown to cross the blood-brain
barrier, resulting in expression in brain tissue. Our findings thus
raise the possibility of delivering the human HO-1 gene to the central
nervous system for transient overexpression of the enzyme activity for
pharmacological or other experimental purposes.
Acute-phase proteins and the acute-phase response play an important
role in the inflammatory process (Baumann, 1994
). Some acute-phase
proteins are thought to possess anti-inflammatory activities due to
their antioxidant properties; HO-1 is among these acute phase proteins
and is induced within minutes by heme and other oxidative
stress-inducing agents such as angiotensin II and hyperoxia (Stocker et
al., 1987
; Ishizaka et al., 1994
; Otterbein et al., 1995
; Suttner et
al., 1999
). The mechanism of the antioxidant effect involved derives,
in part, from the fact that increased HO activity enables removal of
heme, a lipid-soluble transmissible form of the potent pro-oxidant iron
and the generation of the heme metabolite bilirubin, having significant
antioxidant and anticomplement properties (Lleusy and Tomaro, 1994
).
The importance of HO-1 in the protection of cells against the
detrimental effects of oxidative stress is supported by the observation
that humans and mice deficient in the HO-1 gene (Poss and Tonegawa,
1997a
; Yachie et al., 1999
) suffer from severe pathological conditions, including endothelial cell detachment and dysfunction with
subendothelial deposition of foreign material and arterial occlusion.
Recently, direct involvement of HO-1 overexpression in the suppression
of inflammation (Laniado-Schwartzman et al., 1997
) and modulation of
hypertension (da Silva et al., 1994
; Motterlini et al., 1998
), and the
suppression of adhesion molecules (Wagener et al., 1999
) also has been
described. Preinduction of HO-1 inhibits monocyte transmigration
induced by low-density lipoprotein (Ishikawa et al., 1997
). In
contrast, da Silva et al. (1996)
demonstrated that preinduction of HO-1
enhanced cell resistance to oxidative stress; however, long-term
expression had a deleterious effect on cell viability. Thus, whether
HO-1 activity is protective or potentially deleterious is probably a
function, in part, of the degree of enzyme activity.
The apparent effect of the adenoviral-mediated human HO-1 gene on CYP
epoxygenase activity involved in the synthesis of epoxyeicosatrienoic acids is of note. Carbon monoxide and bilirubin, products of HO activity, have been shown to have differential effects on CYP isozymes.
Carbon monoxide inhibits synthesis of CYP isozymes (Estabrook et al.,
1970
); in contrast, bilirubin has been shown to be an inducer of CYP
1A1 and epoxide formation via activation of the aryl hydrocarbon
receptor (Sinal and Bend, 1977
). The resulting divergent effects of
carbon monoxide and bilirubin on CYP epoxygenase remain to be
explained. Our present finding showing a reciprocal decrease in
cellular heme as a result of an increase of HO-1 activity by gene
transfer is in agreement with the commonly observed inverse relationship between CYP and this enzyme activity (Bissell and Hammaker, 1976
; Levere et al., 1990
; Schwartzman et al., 1990
). Whether
exaggerated HO-1 overexpression after administration of metal inducers
or endotoxin (Bissell and Hammaker, 1976
; Levere et al., 1989
;
Schwartzman et al., 1990
) or moderate expression after HO-1 gene
transfer as described in the present report is a major determinant of
other heme-dependent CYP enzyme activities remains to be established.
In summary, this study demonstrates that enhanced heme catabolism,
brought about by adenoviral-mediated human HO-1 gene transfer,
attenuates cellular heme content and heme-dependent enzyme activity.
Furthermore, an increase in HO-1 activity elicited by gene transfer may
be beneficial in the enhancement of carbon monoxide and bilirubin
production; both of these substances play a significant role in renal
circulation and blood flow.
| |
Acknowledgments |
|---|
We thank Chiara Kimmel-Preuss and Jennifer Brown for assistance in preparation of the manuscript.
| |
Footnotes |
|---|
Accepted for publication January 17, 2000.
Received for publication September 14, 1999.
1 This study was supported in part by Grants RO1 HL54138 and EY06531 from the National Institutes of Health.
Send reprint requests to: Nader G. Abraham, Department of Pharmacology, New York Medical College, Valhalla, NY 10595. E-mail: nader_abraham{at}nymc.edu
| |
Abbreviations |
|---|
CYP, cytochrome P-450; HO, heme oxygenase; PCR, polymerase chain reaction; pfu, plaque-forming unit; RT, reverse transcription; bp, base pair(s).
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. G. Abraham and A. Kappas Pharmacological and Clinical Aspects of Heme Oxygenase Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Wang, H. Singh, F. Zhang, T. Ishizuka, H. Deng, R. Kemp, M. S. Wolin, T. H. Hintze, N. G. Abraham, A. Nasjletti, et al. Endothelial Dysfunction and Hypertension in Rats Transduced With CYP4A2 Adenovirus Circ. Res., April 14, 2006; 98(7): 962 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Abraham, R. Rezzani, L. Rodella, A. Kruger, D. Taller, G. Li Volti, A. I. Goodman, and A. Kappas Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2468 - H2477. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sacerdoti, N. G. Abraham, A. O. Oyekan, L. Yang, A. Gatta, and J. C. McGiff Role of the Heme Oxygenases in Abnormalities of the Mesenteric Circulation in Cirrhotic Rats J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 636 - 643. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Abraham, S. Quan, P. A. Mieyal, L. Yang, T. Burke-Wolin, C. J. Mingone, A. I. Goodman, A. Nasjletti, and M. S. Wolin Modulation of cGMP by human HO-1 retrovirus gene transfer in pulmonary microvessel endothelial cells Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1117 - L1124. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. T. Botros, M. Laniado-Schwartzman, and N. G. Abraham Regulation of Cyclooxygenase- and Cytochrome P450-Derived Eicosanoids by Heme Oxygenase in the Rat Kidney Hypertension, February 1, 2002; 39(2): 639 - 644. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Tulis, W. Durante, X. Liu, A. J. Evans, K. J. Peyton, and A. I. Schafer Adenovirus-Mediated Heme Oxygenase-1 Gene Delivery Inhibits Injury-Induced Vascular Neointima Formation Circulation, November 27, 2001; 104(22): 2710 - 2715. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Quan, L. Yang, N. G. Abraham, and A. Kappas Regulation of human heme oxygenase in endothelial cells by using sense and antisense retroviral constructs PNAS, October 9, 2001; 98(21): 12203 - 12208. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||